-
The commercial production of biopharmaceuticals is facing many problems, how to solve them
Time of Update: 2021-09-30
Especially in the current stage of accelerated commercial production of biopharmaceuticals, the industry has generally believed that high-end biopharmaceutical equipment will become an indispensable pharmaceutical aid .
-
The results of the global phase 2/3 clinical trial of the clover new crown candidate vaccine show that the protective effect of the Delta variant strain is 79%
Time of Update: 2021-09-30
A total of more than 30,000 adult and elderly subjects were enrolled in the "SPECTRA" Phase 2/3 clinical trials on four continents around the world. In the analysis of protection effectiveness, 100%
-
Innovent submits a listing application for new indications of Sintilizumab
Time of Update: 2021-09-30
The marketing application is based on the international multi-center phase III clinical (ORIENT-15) data of combined cisplatin and paclitaxel/cisplatin and 5-fluorouracil for the first-line treatment of advanced or metastatic esophageal squamous cell carcinoma .
-
Zheng Xiangling, Chairman of Beijing Tide Pharmaceuticals, was elected as a member of the Hong Kong Special Administrative Region Election Committee
Time of Update: 2021-09-30
On September 19, the 2021 election of the Hong Kong Special Administrative Region Election Committee was successfully concluded.
Zheng Xiangling, executive director of the China Overseas Friendship Association and chairman of the Hong Kong Provincial Committee of the CPPCC Committee, said that the election of the Election Committee was carried out smoothly and orderly.
-
Antu Biocarbohydrate Antigen CA15-3 Calibrator Obtained Medical Device Registration Certificate
Time of Update: 2021-09-30
On September 22, Antu Biological issued an announcement stating that the company had recently received the "Medical Device Registration Certificate" for the carbohydrate antigen CA15-3 calibrator issued by the Henan Provincial Drug Administration for use in the company's fully automated chemiluminescence detection.
-
MS oral new medicine!
Time of Update: 2021-09-30
The results of the primary endpoint showed that compared with Tecfidera, patients treated with Vumerity had a 46% reduction in the number of days with self-reported IGISIS intensity scores ≥2 (adjusted odds ratio [95%CI]: 0.
-
Zhejiang Pharmaceutical Levofloxacin Sodium Chloride Injection Obtained Drug Registration Certificate
Time of Update: 2021-09-30
On September 22, Zhejiang Medicine issued an announcement stating that the company had recently received the "Drug Registration Certificate" for levofloxacin sodium chloride injection 150ml: 0.
-
Chen Yu serves as Vice President of Biological Research and Head of Translational Medicine Research of Yahong New Drug Discovery Department
Time of Update: 2021-09-30
He organized and led a team to commit to the company’s new drug discovery project and translational medicine research in the field of tumor immunotherapy, and promoted multiple projects into clinical and preclinical research.
-
Aerie's new drug for dry eye disease failed in mid-term research, chairman and CEO resigned
Time of Update: 2021-09-30
In the news of the failure to disclose, Anido downplayed its importance, believing that "this is a phase IIb study and there is no need to choose the primary endpoint .
-
Luye Pharma's Alzheimer's innovative drug Liss' Mingdo Day transdermal patch is approved for marketing in the UK
Time of Update: 2021-09-30
Guildford, United Kingdom, September 23, 2021/PRNewswire/ - Luye Pharmaceutical Group announced that its self-developed innovative preparation, Liss’ Mindo Day Transdermal Patch, has been approved by the British Drug and Health Products Regulatory Agency ( Medicines and Healthcare products Regulatory Agency) for the treatment of mild and moderate dementia related to Alzheimer’s disease .
-
All localities are accelerating the implementation of the standard of traditional Chinese medicine formula particles!
Time of Update: 2021-09-30
On August 12, the Shandong Provincial Food and Drug Administration issued the "Shandong Province Traditional Chinese Medicine Formula Granule Production Quality Management Guidelines (Trial)", which put forward quality management requirements for the institutions and personnel of the manufacturing enterprises, plants and facilities, and equipment .
-
Ascent Pharmaceuticals MDM2-p53 inhibitor APG-115 obtained Fast Track qualification from the US FDA for the treatment of relapsed/refractory unresectable/metastatic melanoma
Time of Update: 2021-09-30
HK) announced today that the company’s original innovative drug MDM2-p53 inhibitor alrizomadlin (APG-115) has been granted Fast Track Qualification (FTD) by the US Food and Drug Administration (FDA) for use in tumor immunity Patients with relapsed/refractory unresectable/metastatic melanoma after treatment .
-
Within a week, many pharmaceutical companies such as Jianfan Biological and Jingxin Pharmaceutical were investigated by institutions
Time of Update: 2021-09-30
A number of pharmaceutical companies have recently disclosed the announcements of obtaining institutional research, including Jianfan Biological, Tonghe Pharmaceutical, Jingxin Pharmaceutical, China Resources Sanjiu, etc.
-
With the development of the traditional Chinese medicine industry, pharmaceutical companies urgently need to transform and upgrade
Time of Update: 2021-09-30
According to the "In-depth Research and Investment Prospect Analysis Report of the Traditional Chinese Medicine Industry Market 2021-2025" released by the New Thinking Industry Research Center, the scale of China's traditional Chinese medicine manufacturing market has increased from 64 billion yuan to 73.
-
Bribery, collection and cut-off of Yichang people’s welfare, and Baiao Pharmaceutical’s “blacklist” of dishonesty face heavy penalties
Time of Update: 2021-09-30
According to the announcement, two pharmaceutical companies, Yichang Renfu Pharmaceutical and Beijing Baiao Pharmaceutical, were rated as "serious" in Henan Province's medical prices and credit untrustworthiness due to commercial bribery and centralized procurement .
-
The pharmaceutical track continues to develop well, and many sub-sectors are highly favored by investors
Time of Update: 2021-09-30
After quitting Hengrui Pharmaceutical’s top ten shareholders in 2017, Hillhouse re-purchased more than 40 million shares of Hengrui Pharmaceuticals in the second quarter of this year, becoming one of its largest shareholders, holding a market value of approximately 2.
-
Domestic pharmaceutical companies are vigorously introducing innovative drugs, and hundreds of millions of transactions have become the norm
Time of Update: 2021-09-30
It is understood that since the beginning of this year, domestic pharmaceutical companies have spent huge sums of money to introduce innovative drugs has become the norm in the industry, and transactions with hundreds of millions of dollars are not rare .
-
Under the collection!
Time of Update: 2021-09-29
Who knows that starting from 2020, the state has implemented centralized bidding for products that are currently in large quantities in hospitals and commonly used by the people, and the policy of mass procurement has greatly reduced the number of drugs.
-
Great changes have taken place in the practice system of Chinese physicians!
Time of Update: 2021-09-29
The "Interim Measures" stipulate that after a doctor has been registered and obtained a "Physician's Practicing Certificate", he may engage in corresponding medical treatment, prevention, and health care activities in accordance with the registered practice location, practice category, and practice scope .
-
No entry: Neurology clinic refuses to use Aduhelm, a new drug for Alzheimer's disease
Time of Update: 2021-09-29
According to a note on its website, considering the high price of Aduhelm-the average annual treatment cost per patient is $56,000-and the ambiguous clinical benefits, doctors at the Neurology Center have agreed to refuse to use it until the dispute is clarified.
